HRP20130933T1 - Pripravci sa smanjenom formacijom dimera - Google Patents
Pripravci sa smanjenom formacijom dimera Download PDFInfo
- Publication number
- HRP20130933T1 HRP20130933T1 HRP20130933AT HRP20130933T HRP20130933T1 HR P20130933 T1 HRP20130933 T1 HR P20130933T1 HR P20130933A T HRP20130933A T HR P20130933AT HR P20130933 T HRP20130933 T HR P20130933T HR P20130933 T1 HRP20130933 T1 HR P20130933T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- peptides
- compositions
- dimer formation
- seq
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 title 1
- 239000000539 dimer Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 claims 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims 11
- 238000000034 method Methods 0.000 claims 7
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 3
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 claims 3
- 229940035024 thioglycerol Drugs 0.000 claims 3
- 238000006471 dimerization reaction Methods 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Claims (10)
1. Uporaba trehaloze i tioglicerola u liofiliziranom pripravku koji sadrži peptide SEQ ID Br.: 1 do 4, naznačen time, da je uporaba za sprječavanje ili smanjivanje dimerizacije rečenih peptida u rečenom pripravku.
2. Uporaba u skladu s patentnim zahtjevom 1, naznačena time, da pripravak nadalje sadrži peptide SEQ ID br. 84 do 86.
3. Uporaba u skladu s patentnim zahtjevom 2, naznačena time, da pripravak ne sadrži nikakve daljnje peptide.
4. Postupak proizvodnje stabilnog liofiliziranog pripravka koji sadrži peptide SEQ ID Br.: 1 do 4, naznačen time, da se rečeni postupak sastoji od:
a) priprave pripravka koji u otopini sadrži: (i) trehalozu; (ii) tioglicerol; i (iii) rečene peptide; te
b) liofilizacije pripravka dobivenog iz koraka (a).
5. Postupak u skladu s patentnim zahtjevom 4, naznačen time, da pripravak nadalje sadrži peptide SEQ ID Br. 84 do 86.
6. Postupak u skladu s patentnim zahtjevom 5, naznačen time, da pripravak ne sadrži nikakve daljnje peptide.
7. Postupak rekonstruiranja stabilnog liofiliziranog pripravka dobivenog u skladu s postupkom iz patentnog zahtjeva 5 ili 6, naznačen time, da se rečeni postupak sastoji od rekonstrukcije rečenog liofiliziranog pripravka u otopini.
8. Stabilan, liofilizirani pripravak, naznačen time, da sadrži peptide SEQ ID Br.: 1 do 4, tioglicerol i trehalozu.
9. Pripravak u skladu s patentnim zahtjevom 8, naznačen time, da nadalje sadrži peptide SEQ ID br. 84 do 86.
10. Pripravak u skladu s patentnim zahtjevom 9, naznačen time, da ne sadrži nikakve daljnje peptide.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0821806.7A GB0821806D0 (en) | 2008-11-28 | 2008-11-28 | Compositions with reduced dimer formation |
| PCT/GB2009/002767 WO2010061193A2 (en) | 2008-11-28 | 2009-11-27 | Compositions with reduced dimer formation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20130933T1 true HRP20130933T1 (hr) | 2013-11-08 |
Family
ID=40262373
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20130933AT HRP20130933T1 (hr) | 2008-11-28 | 2013-10-04 | Pripravci sa smanjenom formacijom dimera |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US9180098B2 (hr) |
| EP (2) | EP2373293B2 (hr) |
| JP (2) | JP5612592B2 (hr) |
| KR (1) | KR101669693B1 (hr) |
| CN (1) | CN102227214B (hr) |
| AU (1) | AU2009321358B2 (hr) |
| BR (1) | BRPI0921541A2 (hr) |
| CA (1) | CA2744587C (hr) |
| DK (1) | DK2373293T3 (hr) |
| EA (1) | EA019923B1 (hr) |
| ES (1) | ES2427855T5 (hr) |
| GB (2) | GB0821806D0 (hr) |
| HK (1) | HK1161139A1 (hr) |
| HR (1) | HRP20130933T1 (hr) |
| IL (1) | IL213088A (hr) |
| MX (1) | MX2011005530A (hr) |
| NZ (1) | NZ593145A (hr) |
| PL (1) | PL2373293T3 (hr) |
| SG (1) | SG171438A1 (hr) |
| SI (1) | SI2373293T1 (hr) |
| WO (1) | WO2010061193A2 (hr) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0821806D0 (en) | 2008-11-28 | 2009-01-07 | Circassia Ltd | Compositions with reduced dimer formation |
| JP2015500864A (ja) * | 2011-12-23 | 2015-01-08 | ノバルティス アーゲー | 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）に対して免疫するための安定な組成物 |
| GB201208293D0 (en) | 2012-05-11 | 2012-06-20 | Circassia Ltd | Hydrochlorice salt of peptide |
| GB201209862D0 (en) * | 2012-06-01 | 2012-07-18 | Circassia Ltd | Cladosporium peptides |
| GB201209868D0 (en) * | 2012-06-01 | 2012-07-18 | Circassia Ltd | Alternaria peptides |
| EP2698162A1 (en) * | 2012-08-15 | 2014-02-19 | Credentis AG | Method for producing a composition for treating a tooth lesion |
| RU2687164C2 (ru) | 2012-10-30 | 2019-05-07 | Аравакс Пти Лтд | Новые иммунотерапевтические молекулы и их применения |
| GB201301457D0 (en) | 2013-01-28 | 2013-03-13 | Fluorogenics Ltd | Freeze-dried composition |
| CN103040769A (zh) * | 2013-02-05 | 2013-04-17 | 南京碧迪可医药科技有限公司 | 一种稳定的诺卡沙星粉针冻干剂 |
| US11266737B2 (en) | 2013-09-25 | 2022-03-08 | Aravax Pty Ltd | Immunotherapeutic composition and uses thereof |
| CN103656635B (zh) * | 2013-12-05 | 2016-05-18 | 安徽润敏江生物科技有限公司 | 一种德国小蠊过敏原制剂的制备方法 |
| AU2015245530B2 (en) * | 2014-04-10 | 2019-10-03 | Asit Biotech S.A. | HSP-free allergen preparation |
| WO2016124661A1 (en) * | 2015-02-04 | 2016-08-11 | Universität Zürich | Use of hla-b27 homodimers for cancer treatment |
| CA3004745A1 (en) | 2015-11-12 | 2017-05-18 | University Of Virginia Patent Foundation | Compositions and methods for vas-occlusive contraception and reversal thereof |
| CN108473575B (zh) * | 2015-11-13 | 2022-04-19 | 美国卫生和人力服务部 | 抗-bcma多肽和蛋白质 |
| WO2018029284A1 (en) | 2016-08-10 | 2018-02-15 | Universität Zürich | Mhc class ia open conformers |
| WO2018129369A1 (en) | 2017-01-05 | 2018-07-12 | Contraline, Inc. | Methods for implanting and reversing stimuli-responsive implants |
| KR102649069B1 (ko) | 2018-05-31 | 2024-03-19 | 주식회사 엑소코바이오 | 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 안면 홍조 개선용 조성물 |
| CN112261871B (zh) | 2018-07-28 | 2022-05-17 | 韩国外泌体生技有限公司 | 用于使外排体冻干的方法 |
| KR102163806B1 (ko) | 2018-07-30 | 2020-10-07 | 주식회사 엑소코바이오 | 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물 |
| AU2019380413A1 (en) | 2018-11-13 | 2021-05-20 | Contraline, Inc. | Systems and methods for delivering biomaterials |
| US20240060082A1 (en) * | 2021-01-22 | 2024-02-22 | Syngenta Crop Protection Ag | Soybean Engineered Resistance |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0044532B1 (en) * | 1980-07-18 | 1986-04-23 | E.I. Du Pont De Nemours And Company | Monothioglycerol as thiol-protector in lyophilized materials |
| US4442212A (en) * | 1980-11-10 | 1984-04-10 | E. I. Du Pont De Nemours & Company | Monothioglycerol as thiol-protector in lyophilized materials |
| JPS6197229A (ja) * | 1984-10-18 | 1986-05-15 | Chugai Pharmaceut Co Ltd | 安定なエリトロポエチン製剤 |
| US4855407A (en) | 1985-04-11 | 1989-08-08 | Alpha-1 Biomedicals, Inc. | Solid phase process for synthesizing peptides |
| JP2787162B2 (ja) * | 1989-08-24 | 1998-08-13 | フマキラー株式会社 | 精製ダニアレルゲン |
| AU650249B2 (en) * | 1989-11-03 | 1994-06-16 | Immulogic Pharmaceutical Corporation | A human T cell reactive feline protein (TRFP) isolated from house dust and uses therefor |
| KR100260342B1 (ko) | 1991-10-16 | 2000-07-01 | 스타세이 엘. 첸링 | 더마토파고이드로 부터 유래된 알레르겐의 t세포 에피토프 |
| JPH07507924A (ja) | 1992-04-09 | 1995-09-07 | イミュロジック ファーマスーティカル コーポレイション | アンブロシア・アルテミシフォリア由来の主要アレルゲンのｔ細胞エピトープ |
| US5480972A (en) | 1992-10-30 | 1996-01-02 | The University Of Melbourne | Allergenic proteins from Johnson grass pollen |
| JPH08507436A (ja) | 1992-12-31 | 1996-08-13 | イミュロジック ファーマスーティカル コーポレイション | 犬の鱗屑由来のアレルゲン性蛋白質及びペプチド並びにそれらの利用 |
| AU7726094A (en) | 1994-09-02 | 1996-03-27 | Immulogic Pharmaceutical Corporation | Peptide compositions capable of down regulating an antigen specific immune response |
| DE19508192A1 (de) * | 1995-03-09 | 1996-09-12 | Behringwerke Ag | Stabile Transglutaminasepräparate und Verfahren zu ihrer Herstellung |
| CN1283997A (zh) | 1997-12-22 | 2001-02-14 | 人类基因组科学公司 | 角质形成细胞生长因子－2制剂 |
| GB2348808B (en) * | 1998-01-09 | 2003-03-19 | Circassia Ltd | Methods and compositions for desensitisation |
| WO2002017956A2 (en) | 2000-08-31 | 2002-03-07 | Chiron Corporation | Stabilized fgf formulations containing reducing agents |
| US7741282B2 (en) | 2001-11-13 | 2010-06-22 | Genentech, Inc. | ApO2 ligand/TRAIL formulations |
| CA2469078A1 (en) | 2001-12-05 | 2003-06-12 | Circassia Limited | Immunotherapeutic methods and systems |
| ATE337014T1 (de) * | 2002-03-15 | 2006-09-15 | Natimmune As | Mannose-bindungsprotein enthaltende pharmazeutische zusammensetzungen |
| EP1523326A4 (en) | 2002-05-06 | 2009-09-09 | Univ Jefferson | INSULIN-RELATED PEPTIDES HAVING EFFECTS ON BRAIN HEALTH |
| JP2007534633A (ja) | 2003-11-10 | 2007-11-29 | アライバ−プロメティック インコーポレイティド | ヒト・アルファ１−抗トリプシン製剤 |
| EP1559431B1 (en) | 2003-12-31 | 2007-03-28 | Orthologic Corp. | Pharmaceutical composition for thrombin peptide derivatives |
| JP2007277094A (ja) | 2004-06-29 | 2007-10-25 | Chemo Sero Therapeut Res Inst | 改変ダニ主要アレルゲン含有医薬組成物 |
| US20060029551A1 (en) | 2004-08-05 | 2006-02-09 | Kui Liu | Stable particle formulations of erythropoietin receptor agonists |
| KR20070100832A (ko) | 2005-02-01 | 2007-10-11 | 아테뉴온, 엘엘씨 | 항혈관신생 ｐｈｓｃｎ 펩티드를 함유하는 조성물 |
| WO2006096497A2 (en) | 2005-03-04 | 2006-09-14 | Dynavax Technologies Corporation | Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients |
| WO2006127910A2 (en) | 2005-05-25 | 2006-11-30 | Neose Technologies, Inc. | Glycopegylated erythropoietin formulations |
| US20090155351A1 (en) * | 2005-10-04 | 2009-06-18 | Alk-Abello A/S | Solid Vaccine Formulation |
| EP1958645A1 (en) * | 2007-02-13 | 2008-08-20 | Biomay AG | Peptides derived from the major allergen of ragweed (Ambrosia artemisiifolia) and uses thereof |
| US8148105B2 (en) | 2007-03-16 | 2012-04-03 | The Board Of Trustees Of The Leland Stanford Junior University | Scaleable manufacturing process for cysteine endoprotease B, isoform 2 |
| GB0710529D0 (en) * | 2007-06-01 | 2007-07-11 | Circassia Ltd | Vaccine |
| ATE482721T1 (de) | 2007-08-15 | 2010-10-15 | Circassia Ltd | Peptide zur desensibilisierung gegenüber allergenen |
| GB0821806D0 (en) | 2008-11-28 | 2009-01-07 | Circassia Ltd | Compositions with reduced dimer formation |
-
2008
- 2008-11-28 GB GBGB0821806.7A patent/GB0821806D0/en not_active Ceased
-
2009
- 2009-11-27 KR KR1020117014702A patent/KR101669693B1/ko active IP Right Grant
- 2009-11-27 CN CN200980147921.8A patent/CN102227214B/zh not_active Expired - Fee Related
- 2009-11-27 JP JP2011538050A patent/JP5612592B2/ja not_active Expired - Fee Related
- 2009-11-27 EP EP09760560.4A patent/EP2373293B2/en not_active Not-in-force
- 2009-11-27 BR BRPI0921541A patent/BRPI0921541A2/pt not_active IP Right Cessation
- 2009-11-27 GB GB1114575.2A patent/GB2479515B/en not_active Expired - Fee Related
- 2009-11-27 CA CA2744587A patent/CA2744587C/en not_active Expired - Fee Related
- 2009-11-27 SI SI200930730T patent/SI2373293T1/sl unknown
- 2009-11-27 PL PL09760560T patent/PL2373293T3/pl unknown
- 2009-11-27 DK DK09760560.4T patent/DK2373293T3/da active
- 2009-11-27 ES ES09760560.4T patent/ES2427855T5/es active Active
- 2009-11-27 EP EP13176176.9A patent/EP2649990A1/en not_active Withdrawn
- 2009-11-27 WO PCT/GB2009/002767 patent/WO2010061193A2/en active Application Filing
- 2009-11-27 SG SG2011038718A patent/SG171438A1/en unknown
- 2009-11-27 US US13/131,505 patent/US9180098B2/en not_active Expired - Fee Related
- 2009-11-27 EA EA201100865A patent/EA019923B1/ru not_active IP Right Cessation
- 2009-11-27 NZ NZ593145A patent/NZ593145A/xx not_active IP Right Cessation
- 2009-11-27 MX MX2011005530A patent/MX2011005530A/es active IP Right Grant
- 2009-11-27 AU AU2009321358A patent/AU2009321358B2/en not_active Ceased
-
2011
- 2011-05-24 IL IL213088A patent/IL213088A/en not_active IP Right Cessation
-
2012
- 2012-02-29 HK HK12102043.9A patent/HK1161139A1/xx not_active IP Right Cessation
-
2013
- 2013-10-04 HR HRP20130933AT patent/HRP20130933T1/hr unknown
-
2014
- 2014-09-04 JP JP2014180264A patent/JP5905942B2/ja not_active Expired - Fee Related
-
2015
- 2015-10-06 US US14/876,548 patent/US9375470B2/en active Active
-
2016
- 2016-05-24 US US15/163,211 patent/US20160367660A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20130933T1 (hr) | Pripravci sa smanjenom formacijom dimera | |
| HRP20210394T1 (hr) | Moduliranje specifičnosti strukturiranog polipeptida | |
| HRP20192314T1 (hr) | Pripravci faktora viii i postupci pripreme i njihove uporabe | |
| MY194925A (en) | Composition of fish skin collagen peptides and use thereof as a drug | |
| HRP20190982T1 (hr) | Peptidi i njihova uporaba | |
| NZ621868A (en) | Growth hormone polypeptides and methods of making and using same | |
| NZ710626A (en) | Pcsk9 vaccine | |
| JP2015525217A5 (hr) | ||
| NZ630484A (en) | Compositions and methods for treatment of metabolic disorders and diseases | |
| RU2534564C3 (ru) | Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii | |
| JP2016500250A5 (hr) | ||
| NZ630469A (en) | Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases | |
| RU2021134101A (ru) | Модифицированная j-цепь | |
| PE20140982A1 (es) | Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta | |
| NZ707439A (en) | Modified factor ix polypeptides and uses thereof | |
| EP2594581A3 (en) | Peptide vaccines with Seq Id No: 178, 174, 186 or 194 for cancers expressing tumor-associated antigens | |
| AR086998A1 (es) | Coagonistas del receptor de glucagon/glp-1 | |
| RU2014103288A (ru) | Слитые полипептиды релаксина и их применение | |
| EA200801460A1 (ru) | Рекомбинантные моновалентные антитела и способы их получения | |
| RU2015119517A (ru) | Новый способ лечения инфаркта миокарда с применением фрагмента hmgb1 | |
| RU2011154363A (ru) | Комбинации клад rrgb пневмококков | |
| MY180953A (en) | Acyl-acp thioesterase | |
| JP2015524403A5 (hr) | ||
| JP2012529293A5 (hr) | ||
| WO2013096868A3 (en) | Saposin-a derived peptides and uses thereof |